GoAI
Get started
Surgery Partners, Inc. logo

Surgery Partners, Inc.

SGRY

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$14.52

+$0.58 · +4.16%

Aug 21, 4:00 PM ET

SGRY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

85

Deep Value

Momentum

52

Neutral

Sentiment

59

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical venues include both ambulatory surgery centers and dedicated surgical hospitals, delivering non-urgent surgical procedures across various specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The surgical hospitals additionally offer comprehensive ancillary services, including diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care. The dedicated Ancillary Services segment further encompasses multi-specialty physician practices, urgent care facilities, and anesthesia services. By December 31, 2021, the company's portfolio consisted of 126 surgical facilities—specifically, 108 ambulatory surgical centers and 18 surgical hospitals—situated across 31 states. Founded in 2004, Surgery Partners, Inc. maintains its headquarters in Brentwood, Tennessee.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
J. Eric Evans
Listed since
Sep 30, 2015
Employees
16,000

Market position

Day range

Current $14.52

52-week range

Current $14.52

Open
$14.10
Previous close
$13.94
Volume
3.88M
2.38× average
Average volume
1.63M
Average daily volume
Market cap
1.9B USD
Beta
1.94
Market reference 1
50-day average
$15.541
-6.57% below average
200-day average
$14.9515
-2.89% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.75B USD
P/E (TTM)
-21.04×
P/B (TTM)
1.12×
P/S (TTM)
0.56×
EV / EBITDA
10.17×
Earnings yield
-3.96%
Free cash flow yield
9.95%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
21.37%
Operating margin
11.89%
Net margin
-2.63%
Return on equity
-4.55%
Return on assets
-0.95%
Return on invested capital
4.24%

Financial health

Debt / equity
2.4×
Current ratio
1.87×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends27%15%3%-8%Gross margin, FY2021: 22.08%Gross margin, FY2022: 22.64%Gross margin, FY2023: 23.60%Gross margin, FY2024: 23.94%Gross margin, FY2025: 23.12%Operating margin, FY2021: 13.58%Operating margin, FY2022: 13.59%Operating margin, FY2023: 11.96%Operating margin, FY2024: 11.20%Operating margin, FY2025: 11.77%Net margin, FY2021: -3.19%Net margin, FY2022: -2.15%Net margin, FY2023: -0.43%Net margin, FY2024: -5.40%Net margin, FY2025: -2.35%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 22.08%. Gross margin FY2022 22.64%. Gross margin FY2023 23.60%. Gross margin FY2024 23.94%. Gross margin FY2025 23.12%. Operating margin FY2021 13.58%. Operating margin FY2022 13.59%. Operating margin FY2023 11.96%. Operating margin FY2024 11.20%. Operating margin FY2025 11.77%. Net margin FY2021 -3.19%. Net margin FY2022 -2.15%. Net margin FY2023 -0.43%. Net margin FY2024 -5.40%. Net margin FY2025 -2.35%.

Income trends

Revenue

3.31B USD+6.24%

Operating income

389.5M USD+11.67%

Net income

−77.9M USD+53.66%
Income trends across reported periods3.66B USD2.27B USD874.94M USD−515.78M USDRevenue, FY2021: 2.23B USDRevenue, FY2022: 2.54B USDRevenue, FY2023: 2.74B USDRevenue, FY2024: 3.11B USDRevenue, FY2025: 3.31B USDOperating income, FY2021: 302.2M USDOperating income, FY2022: 345.2M USDOperating income, FY2023: 328M USDOperating income, FY2024: 348.8M USDOperating income, FY2025: 389.5M USDNet income, FY2021: −70.9M USDNet income, FY2022: −54.6M USDNet income, FY2023: −11.9M USDNet income, FY2024: −168.1M USDNet income, FY2025: −77.9M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.23B USD. Revenue FY2022 2.54B USD. Revenue FY2023 2.74B USD. Revenue FY2024 3.11B USD. Revenue FY2025 3.31B USD. Operating income FY2021 302.2M USD. Operating income FY2022 345.2M USD. Operating income FY2023 328M USD. Operating income FY2024 348.8M USD. Operating income FY2025 389.5M USD. Net income FY2021 −70.9M USD. Net income FY2022 −54.6M USD. Net income FY2023 −11.9M USD. Net income FY2024 −168.1M USD. Net income FY2025 −77.9M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.31B USD3.11B USD2.74B USD2.54B USD2.23B USD
Cost of goods sold2.54B USD2.37B USD2.1B USD1.96B USD1.73B USD
Gross profit765M USD745.6M USD647.5M USD574.9M USD491.4M USD
Selling, general, and administrative522.7M USD138.7M USD120.9M USD102.2M USD104M USD
Operating expenses375.5M USD396.8M USD319.5M USD229.7M USD189.2M USD
Interest expense272.6M USD201.7M USD193M USD234.9M USD221M USD
Depreciation and amortization176M USD152.6M USD118.1M USD114.8M USD98.8M USD
Operating income389.5M USD348.8M USD328M USD345.2M USD302.2M USD
Net income−77.9M USD−168.1M USD−11.9M USD−54.6M USD−70.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
+6.32%
11 comparable reports
Latest EPS result
0.1
Estimate 0.06 · Beat by 72.59%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.490.260.03-0.2Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 0.44, estimate 0.38, surprise +15.79%, Beat. Q2 2025, reported May 12, 2025: actual 0.04, estimate 0.08, surprise -50.00%, Miss. Q3 2025, reported Aug 5, 2025: actual 0.17, estimate 0.16, surprise +6.25%, Beat. Q4 2025, reported Nov 10, 2025: actual 0.13, estimate 0.19, surprise -31.58%, Miss. Q1 2026, reported Mar 2, 2026: actual 0.12, estimate 0.31, surprise -61.29%, Miss. Q2 2026, reported May 5, 2026: actual -0.03, estimate -0.15, surprise +80.00%, Beat. Q3 2026, reported Aug 10, 2026: actual 0.1, estimate 0.058, surprise +72.59%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 0.09, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates920.4M860.47M800.53M740.6MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 3, 2025: actual 864.4M USD, estimate 800.08M USD, surprise +8.04%, Beat. Q2 2025, reported May 12, 2025: actual 776M USD, estimate 777.07M USD, surprise -0.14%, Miss. Q3 2025, reported Aug 5, 2025: actual 826.2M USD, estimate 823.55M USD, surprise +0.32%, Beat. Q4 2025, reported Nov 10, 2025: actual 821.5M USD, estimate 866.54M USD, surprise -5.20%, Miss. Q1 2026, reported Mar 2, 2026: actual 885M USD, estimate 866.82M USD, surprise +2.10%, Beat. Q2 2026, reported May 5, 2026: actual 810.9M USD, estimate 797.69M USD, surprise +1.66%, Beat. Q3 2026, reported Aug 10, 2026: actual 848.9M USD, estimate 830.03M USD, surprise +2.27%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 854.78M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

22 ratings
Strong buy00%
Buy1464%
Hold836%
Sell00%
Strong sell00%

SGRY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SGRY

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
38.21M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
28.62M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
27.84M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
17.65M
Weight
0.03%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
13.62M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
10.22M
Weight
0.07%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Dimensional - US Small Cap Value ETF logoDimensional - US Small Cap Value ETFDFSV
Market value
9.72M
Weight
0.12%
AUM
8.42B USD
Expense ratio
0.30%
Price / 1D
$40.29+0.72%
Dimensional - US Targeted Value ETF logoDimensional - US Targeted Value ETFDFAT
Market value
8.46M
Weight
0.06%
AUM
14.66B USD
Expense ratio
0.28%
Price / 1D
$71.67+0.67%

Continue in GoAI

Research SGRY

research.disclaimer